Search

everythinglearnresearchcommunity

for

Search:↓

The four main causes of hair loss in children are fungal infections, pulling out hair, autoimmune hair loss, and stress-related hair shedding.

Early high-dose steroid treatment helps prolong disease-free periods in severe alopecia areata.

Effective treatments for severe alopecia areata are still lacking.

High-dose corticosteroids and methotrexate had a modest effect on severe childhood alopecia, but side effects and relapse were concerns.

Methylprednisolone infusions can help some people with severe alopecia regrow hair.

Some people with severe, long-lasting baldness responded well to a specific combination treatment.

Cyclosporine combined with corticosteroids is more effective for severe alopecia areata than cyclosporine alone.

Using a nonablative fractional laser with topical minoxidil can effectively and safely promote hair regrowth in alopecia areata patients.

JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Early onset, severe types, nail changes, family history, and body hair loss worsen alopecia areata prognosis; sticking to treatment helps.

Herbal lotions are effective for severe hair loss, with a 64.8% success rate, but relapse is common and long-term management requires allergen control and possible corticosteroid use.

Proper diagnosis and treatment of childhood hair loss require distinguishing between alopecia and trichotillomania.

The analysis aims to identify the most effective and safest treatments for alopecia areata.

Treatments for autoimmune hair loss have limited success and patients need emotional support and self-acceptance.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Tofacitinib is an effective and safe treatment for alopecia areata.

Alopecia areata causes hair loss with varied treatment responses and frequent relapses.

Six genetic conditions are often linked to complete scalp hair loss in children.

Diphenylcyclopropenone topical immunotherapy is effective for treating alopecia areata, with some side effects.

Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.

The treatment is effective and safe for severe alopecia areata in children, but not for total or universal hair loss.

Alopecia areata is a hair loss condition that often starts before age 30 and can affect various body parts, with unpredictable hair regrowth chances.

Most patients with alopecia areata in China have patchy hair loss, with total hair loss being less common, and the condition often starts around age 35 and can negatively affect quality of life, especially in more severe cases.

Alopecia areata has different forms and can significantly affect quality of life, especially in more severe cases.

The study concluded that patients with total hair loss and recurring hair loss had an earlier onset, longer-lasting condition, and a greater negative impact on their quality of life, with allergic conditions linked to more severe hair loss.

Alopecia areata in infants may be more common than previously thought.

Alopecia areata was most common in people in their 30s and 40s, with some family history and a higher relapse rate, and larger bald areas responded better to specific immunotherapy.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

The first Japanese family with Marie Unna hereditary hypotrichosis showed hair condition improvement in a child and highlighted the risk of misdiagnosis.